WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 534604
CAS#: 40045-50-9
Description: Halicin ia s novel inhibitor of the c-Jun N-Terminal kinase.
MedKoo Cat#: 534604
Name: Halicin
CAS#: 40045-50-9
Chemical Formula: C5H3N5O2S3
Exact Mass: 260.9449
Molecular Weight: 261.292
Elemental Analysis: C, 22.98; H, 1.16; N, 26.80; O, 12.25; S, 36.81
Synonym: Halicin; SU-3327; SU 3327; SU3327
IUPAC/Chemical Name: 5-[(5-Ntro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine
InChi Key: NQQBNZBOOHHVQP-UHFFFAOYSA-N
InChi Code: InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8)
SMILES Code: NC1=NN=C(SC2=NC=C([N+]([O-])=O)S2)S1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 261.292 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kutlu Z, Celik M, Bilen A, Halıcı Z, Yıldırım S, Karabulut S, Karakaya S, Bostanlık DF, Aydın P. Effects of umbelliferone isolated from the Ferulago pauciradiata Boiss. & Heldr. Plant on cecal ligation and puncture-induced sepsis model in rats. Biomed Pharmacother. 2020 May 4;127:110206. doi: 10.1016/j.biopha.2020.110206. Epub ahead of print. PMID: 32407990.
2: Polat G, Ugan RA, Cadirci E, Halici Z. Sepsis and Septic Shock: Current Treatment Strategies and New Approaches. Eurasian J Med. 2017 Feb;49(1):53-58. doi: 10.5152/eurasianjmed.2017.17062. PMID: 28416934; PMCID: PMC5389495.
3: Emet M, Ozcan H, Ozel L, Yayla M, Halici Z, Hacimuftuoglu A. A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med. 2016 Jun;48(2):135-41. doi: 10.5152/eurasianjmed.2015.0267. PMID: 27551178; PMCID: PMC4970552.
4: Seyrek M, Halici Z, Yildiz O, Ulusoy HB. Interaction between dexmedetomidine and α-adrenergic receptors: emphasis on vascular actions. J Cardiothorac Vasc Anesth. 2011 Oct;25(5):856-62. doi: 10.1053/j.jvca.2011.06.006. Epub 2011 Sep 8. PMID: 21862350.
5: Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z. Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers. Inflammation. 2010 Aug;33(4):224-34. doi: 10.1007/s10753-009-9176-5. PMID: 20084447.
6: Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem. 2008;15(3):278-83. doi: 10.2174/092986708783497247. PMID: 18333314.
